Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient aged ≥ 65 years with mCRPC previously treated with docetaxel~2. Medical or surgical castration with castrate level of testosterone (\< 50 ng/dl) based on the EAU definition of castrate level of testosterone~3. Progressive disease according to PCWG2~4. Histologically proven prostate carcinoma~5. Health status allowing use of chemotherapy: G8 \> 14; or G8 score ≤ 14 with geriatric assessment concluding to reversible impairment allowing use of chemotherapy~6. ECOG-PS 0, 1 or 2(ECOG-PS 2 should be related to prostate cancer)~7. Adequate hematologic, liver and renal functions:~   1. Neutrophil count ≥1.5 109/L~  2. Haemoglobin ≥10 g/ dL~  3. Platelet count ≥100.109/L~  4. Total bilirubin ≤ 1 the upper limit of normal (ULN)~  5. Transaminases ≤ 1.5 ULN~  6. Serum creatinine ≤ 2.0 ULN~8. Ongoing LHRH therapy at study entry~9. Signed informed consent~Exclusion Criteria:~1. History of severe hypersensitivity reaction (≥grade 3) to docetaxel~2. History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs~3. Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus)~4. Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) (see Appendix E)~5. PS \>2 not related to prostate cancer disease~6. G8 ≤ 14 with geriatric assessment contra-indicating standard cabazitaxel regimen~7. Concomitant vaccination with yellow fever vaccine~8. Patient who cannot be regularly followed or cannot answer to quality of life questionnaires because of psychological, social, familial or geographic reasons~9. Participation in another clinical trial with any investigational drug within 30 days prior to study enrolment.

- Gender: MALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).~Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.
- Arm B (Type: EXPERIMENTAL): Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.

Based on this trial design, predict the completion outcome and termination type (if applicable).